Krystal looks to Phase III as stock soars on data for gene therapy

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 25, 2019 at 9:32 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via With its lead gene therapy showing efficacy in healing wounds in a rare skin condition, Krystal has seen its market cap multiply sixfold since its 2017 IPO as it now looks ahead to starting Phase III testing in a matter of months.

    article source